A detailed history of New Edge Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 12,923 shares of VRTX stock, worth $5.88 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
12,923
Previous 10,304 25.42%
Holding current value
$5.88 Million
Previous $4.19 Million 28.84%
% of portfolio
0.05%
Previous 0.04%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $1.07 Million - $1.17 Million
2,619 Added 25.42%
12,923 $5.4 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $222,950 - $266,942
650 Added 6.73%
10,304 $4.19 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $381,467 - $408,854
1,128 Added 13.23%
9,654 $3.36 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $953,950 - $1.07 Million
3,034 Added 55.24%
8,526 $3 Million
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $74,206 - $84,652
-262 Reduced 4.55%
5,492 $1.73 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $78,584 - $88,407
-275 Reduced 4.56%
5,754 $1.66 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $370,765 - $413,687
1,354 Added 28.96%
6,029 $1.75 Million
Q2 2022

Aug 09, 2022

BUY
$234.96 - $292.55 $1.1 Million - $1.37 Million
4,675 New
4,675 $1.32 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $855,345 - $1.01 Million
-3,863 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$177.01 - $223.45 $402,874 - $508,572
2,276 Added 143.42%
3,863 $848,000
Q3 2021

Oct 29, 2021

SELL
$181.39 - $202.99 $55,323 - $61,911
-305 Reduced 16.12%
1,587 $288,000
Q2 2021

Jul 22, 2021

BUY
$187.49 - $221.1 $100,119 - $118,067
534 Added 39.32%
1,892 $381,000
Q1 2021

Apr 26, 2021

SELL
$207.02 - $241.31 $192,735 - $224,659
-931 Reduced 40.67%
1,358 $292,000
Q4 2020

Jan 27, 2021

SELL
$207.01 - $276.09 $2.77 Million - $3.69 Million
-13,367 Reduced 85.38%
2,289 $541,000
Q3 2020

Nov 03, 2020

BUY
$255.65 - $303.1 $3.16 Million - $3.75 Million
12,370 Added 376.45%
15,656 $4.26 Million
Q2 2020

Jul 29, 2020

BUY
$225.48 - $295.8 $342,729 - $449,616
1,520 Added 86.07%
3,286 $954,000
Q1 2020

May 04, 2020

BUY
$199.77 - $247.81 $158,617 - $196,761
794 Added 81.69%
1,766 $420,000
Q4 2019

Jan 31, 2020

BUY
$166.71 - $223.91 $162,042 - $217,640
972 New
972 $212,000
Q2 2019

Aug 05, 2019

SELL
$164.61 - $190.37 $210,700 - $243,673
-1,280 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $209,574 - $249,216
1,280 New
1,280 $235,000
Q1 2019

May 09, 2019

SELL
$163.73 - $194.7 $204,662 - $243,375
-1,250 Closed
0 $0
Q4 2018

Jan 29, 2019

BUY
$151.91 - $192.21 $189,887 - $240,262
1,250 New
1,250 $207,000
Q3 2017

Nov 13, 2017

SELL
$148.13 - $162.24 $16,442 - $18,008
-111 Closed
0 $0
Q2 2017

Aug 16, 2017

BUY
N/A
111
111 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.